Main Article Content
Aim: To compare the therapeutic efficacy and safety of Rupatadine and mometasone with Levocetirizine which is most commonly used drug. To study the effects of levocetirizine, Rupatadine and mometasone on absolute eosinophil count and IgE levels. Methodology: The participants were randomly divided into 3 groups of 25 patients each and treated as follows: Group I: were treated with Levocetirizine 5mg OD for 14 days, Group II: were treated with Rupatadine 10mg OD for 14 days, Group III: were treated with Mometasone two sprays (50mcg of mometasone in each spray) in each nostril once daily (total daily dose of 200mcg) for 14 days. The patients were asked to report at the hospital after 14 day and they were followed up with regard to clinical improvement of symptoms and signs and any adverse effects as reported by the patient. Rhinoscopy finding, X- ray of para nasal sinus, improvement in symptoms (sneezing, Itching, nasal discharge, nasal blockage and anosmia) Absolute eosinophils count, Serum IgE levels and adverse reports were studied and investigation were compared before and after treatment. Result: Rhinoscope finding showed treatment with mometasone became normal but X- Ray of para nasal sinus results showed levocetirzine showed higher rate of improvement. In improvement of symptoms sneezing, itching and nasal discharge was high mometasone. In all groups post treatment there was no changes in Ig E and Absolute Eosinophils count. ADR reported with mometaxone. Conclusion: The three drugs, levocetirizine, rupatadine and mometasone were found to have similar levels of efficacy in controlling the symptoms of the allergic rhinitis. The physical signs improved better with mometasone than the other 2 drugs. The 3 drugs levocetirizine, rupatadine and mometasone had no significant effect on the absolute eosinophil count and the serum IgE levels. Adverse effects were found to be more with levocetirizine than the other two drugs. Considering this factor and also the fact that long term use of corticosteroids like mometasone is undesirable, rupatadine appears to be a better choice in the treatment of allergic rhinitis.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.